- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03989232
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN FORTE)
Efficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kozloduy, Bulgaria, 3320
- Novo Nordisk INvestigational Site
-
Montana, Bulgaria, 3400
- Novo Nordisk INvestigational Site
-
Petrich, Bulgaria, 2850
- Novo Nordisk INvestigational Site
-
Sofia, Bulgaria, 1431
- Novo Nordisk INvestigational Site
-
Sofia, Bulgaria, 1407
- Novo Nordisk INvestigational Site
-
Stara Zagora, Bulgaria, 6000
- Novo Nordisk INvestigational Site
-
Yambol, Bulgaria, 8600
- Novo Nordisk INvestigational Site
-
-
-
-
Newfoundland and Labrador
-
Mount Pearl, Newfoundland and Labrador, Canada, A1N 1W7
- Novo Nordisk INvestigational Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6S 0C6
- Novo Nordisk INvestigational Site
-
Brampton, Ontario, Canada, L6T 0G1
- Novo Nordisk INvestigational Site
-
Etobicoke, Ontario, Canada, M9R 4E1
- Novo Nordisk INvestigational Site
-
London, Ontario, Canada, N5W 6A2
- Novo Nordisk INvestigational Site
-
Markham, Ontario, Canada, L3P 7P2
- Novo Nordisk INvestigational Site
-
Stoney Creek, Ontario, Canada, L8J 0B6
- Novo Nordisk INvestigational Site
-
Toronto, Ontario, Canada, M4G 3E8
- Novo Nordisk INvestigational Site
-
-
-
-
-
Ceske Budejovice, Czechia, 370 01
- Novo Nordisk INvestigational Site
-
Praha 10, Czechia, 102 00
- Novo Nordisk INvestigational Site
-
Praha 5, Czechia, 150 00
- Novo Nordisk INvestigational Site
-
Vlasim, Czechia, 25801
- Novo Nordisk INvestigational Site
-
-
-
-
-
Athens, Greece, GR-17562
- Novo Nordisk INvestigational Site
-
Athens, Greece, GR-11527
- Novo Nordisk INvestigational Site
-
Athens, Greece, 115 25
- Novo Nordisk INvestigational Site
-
Athens, Greece, GR-11521
- Novo Nordisk INvestigational Site
-
Athens, Greece, GR-10676
- Novo Nordisk INvestigational Site
-
Thessaloniki, Greece, GR-57010
- Novo Nordisk INvestigational Site
-
Thessaloniki, Greece, GR-57001
- Novo Nordisk INvestigational Site
-
Thessaloniki, Greece, GR-54642
- Novo Nordisk INvestigational Site
-
-
-
-
-
Budapest, Hungary, 1125
- Novo Nordisk INvestigational Site
-
Budapest, Hungary, 1042
- Novo Nordisk INvestigational Site
-
Budapest, Hungary, 1089
- Novo Nordisk INvestigational Site
-
Budapest, Hungary, 1132
- Novo Nordisk INvestigational Site
-
Budapest, Hungary, 1152
- Novo Nordisk INvestigational Site
-
Budapest, Hungary, 1131
- Novo Nordisk INvestigational Site
-
Debrecen, Hungary, 4043
- Novo Nordisk INvestigational Site
-
Debrecen, Hungary, H-4032
- Novo Nordisk INvestigational Site
-
Kaposvár, Hungary, 7400
- Novo Nordisk INvestigational Site
-
Komarom, Hungary, 2900
- Novo Nordisk INvestigational Site
-
Szeged, Hungary, H-6725
- Novo Nordisk INvestigational Site
-
Szekszárd, Hungary, 7100
- Novo Nordisk INvestigational Site
-
-
-
-
-
Tokyo, Japan, 103-0027
- Novo Nordisk INvestigational Site
-
Tokyo, Japan, 104-0031
- Novo Nordisk INvestigational Site
-
-
-
-
-
Bialystok, Poland, 15-404
- Novo Nordisk INvestigational Site
-
Bialystok, Poland, 15-435
- Novo Nordisk INvestigational Site
-
Gdansk, Poland, 80-214
- Novo Nordisk INvestigational Site
-
Gorzow Wielkopolski, Poland, 66-400
- Novo Nordisk INvestigational Site
-
Katowice, Poland, 40-752
- Novo Nordisk INvestigational Site
-
Lodz, Poland, 90-242
- Novo Nordisk INvestigational Site
-
Lodz, Poland, 91-849
- Novo Nordisk INvestigational Site
-
Lublin, Poland, 20-044
- Novo Nordisk INvestigational Site
-
Warszawa, Poland, 02-097
- Novo Nordisk INvestigational Site
-
Wroclaw, Poland, 52-416
- Novo Nordisk INvestigational Site
-
-
-
-
-
Manati, Puerto Rico, 00674
- Novo Nordisk INvestigational Site
-
-
-
-
-
Bratislava, Slovakia, 83103
- Novo Nordisk INvestigational Site
-
Hnusta, Slovakia, 98101
- Novo Nordisk INvestigational Site
-
Kezmarok, Slovakia, 06001
- Novo Nordisk INvestigational Site
-
Kosice, Slovakia, 04022
- Novo Nordisk INvestigational Site
-
Krupina, Slovakia, 96301
- Novo Nordisk INvestigational Site
-
Levice, Slovakia, 93401
- Novo Nordisk INvestigational Site
-
Nove Zamky, Slovakia, 94070
- Novo Nordisk INvestigational Site
-
Pezinok, Slovakia, 90201
- Novo Nordisk INvestigational Site
-
Poprad, Slovakia, 05801
- Novo Nordisk INvestigational Site
-
Povazska Bystrica, Slovakia, 01701
- Novo Nordisk INvestigational Site
-
Puchov, Slovakia, 02001
- Novo Nordisk INvestigational Site
-
-
-
-
-
Dnipro, Ukraine, 49038
- Novo Nordisk INvestigational Site
-
Mykolaiv, Ukraine, 54003
- Novo Nordisk INvestigational Site
-
Ternopil, Ukraine, 46002
- Novo Nordisk INvestigational Site
-
Vinnytsia, Ukraine, 21010
- Novo Nordisk INvestigational Site
-
Zhytomyr, Ukraine, 10002
- Novo Nordisk INvestigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Novo Nordisk INvestigational Site
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Novo Nordisk INvestigational Site
-
Glendale, Arizona, United States, 85306
- Novo Nordisk INvestigational Site
-
Glendale, Arizona, United States, 85308
- Novo Nordisk INvestigational Site
-
Mesa, Arizona, United States, 85213
- Novo Nordisk INvestigational Site
-
Phoenix, Arizona, United States, 85050
- Novo Nordisk INvestigational Site
-
-
California
-
Buena Park, California, United States, 90620
- Novo Nordisk INvestigational Site
-
Fresno, California, United States, 93720
- Novo Nordisk INvestigational Site
-
Los Angeles, California, United States, 90057
- Novo Nordisk INvestigational Site
-
San Diego, California, United States, 92103
- Novo Nordisk INvestigational Site
-
Spring Valley, California, United States, 91978
- Novo Nordisk INvestigational Site
-
Walnut Creek, California, United States, 94598
- Novo Nordisk INvestigational Site
-
West Hills, California, United States, 91304
- Novo Nordisk INvestigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80906
- Novo Nordisk INvestigational Site
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Novo Nordisk INvestigational Site
-
Hollywood, Florida, United States, 33024
- Novo Nordisk INvestigational Site
-
Jacksonville, Florida, United States, 32216
- Novo Nordisk INvestigational Site
-
-
Georgia
-
Adairsville, Georgia, United States, 30103
- Novo Nordisk INvestigational Site
-
Alpharetta, Georgia, United States, 30022
- Novo Nordisk INvestigational Site
-
Roswell, Georgia, United States, 30076
- Novo Nordisk INvestigational Site
-
-
Idaho
-
Meridian, Idaho, United States, 83646
- Novo Nordisk INvestigational Site
-
-
Illinois
-
Carlinville, Illinois, United States, 62626
- Novo Nordisk INvestigational Site
-
Chicago, Illinois, United States, 60607
- Novo Nordisk INvestigational Site
-
Peoria, Illinois, United States, 61603
- Novo Nordisk INvestigational Site
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Novo Nordisk INvestigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Novo Nordisk INvestigational Site
-
Louisville, Kentucky, United States, 40213
- Novo Nordisk INvestigational Site
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- Novo Nordisk INvestigational Site
-
-
Michigan
-
Sterling Heights, Michigan, United States, 48310-3503
- Novo Nordisk INvestigational Site
-
-
Missouri
-
Jefferson City, Missouri, United States, 65109
- Novo Nordisk INvestigational Site
-
-
Montana
-
Butte, Montana, United States, 59701
- Novo Nordisk INvestigational Site
-
-
New Jersey
-
Trenton, New Jersey, United States, 08611
- Novo Nordisk INvestigational Site
-
-
New York
-
New Windsor, New York, United States, 12553
- Novo Nordisk INvestigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Novo Nordisk INvestigational Site
-
Greensboro, North Carolina, United States, 27408
- Novo Nordisk INvestigational Site
-
Salisbury, North Carolina, United States, 28144
- Novo Nordisk INvestigational Site
-
Statesville, North Carolina, United States, 28625
- Novo Nordisk INvestigational Site
-
Wilmington, North Carolina, United States, 28401
- Novo Nordisk INvestigational Site
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Novo Nordisk INvestigational Site
-
Mason, Ohio, United States, 45040-6815
- Novo Nordisk INvestigational Site
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
- Novo Nordisk INvestigational Site
-
-
Oregon
-
Corvallis, Oregon, United States, 97330-3737
- Novo Nordisk INvestigational Site
-
-
South Carolina
-
Gaffney, South Carolina, United States, 29341
- Novo Nordisk INvestigational Site
-
Greenville, South Carolina, United States, 29615
- Novo Nordisk INvestigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Novo Nordisk INvestigational Site
-
Kingsport, Tennessee, United States, 37660
- Novo Nordisk INvestigational Site
-
Memphis, Tennessee, United States, 38119
- Novo Nordisk INvestigational Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Novo Nordisk INvestigational Site
-
Dallas, Texas, United States, 75390-9302
- Novo Nordisk INvestigational Site
-
Houston, Texas, United States, 77074
- Novo Nordisk INvestigational Site
-
Humble, Texas, United States, 77338
- Novo Nordisk INvestigational Site
-
Hurst, Texas, United States, 76054
- Novo Nordisk INvestigational Site
-
Katy, Texas, United States, 77450
- Novo Nordisk INvestigational Site
-
Plano, Texas, United States, 75075
- Novo Nordisk INvestigational Site
-
San Antonio, Texas, United States, 78229
- Novo Nordisk INvestigational Site
-
San Antonio, Texas, United States, 78230
- Novo Nordisk INvestigational Site
-
Shavano Park, Texas, United States, 78231
- Novo Nordisk INvestigational Site
-
Sugar Land, Texas, United States, 77479
- Novo Nordisk INvestigational Site
-
-
Washington
-
Olympia, Washington, United States, 98502
- Novo Nordisk INvestigational Site
-
Walla Walla, Washington, United States, 99362-4445
- Novo Nordisk INvestigational Site
-
Wenatchee, Washington, United States, 98801-2028
- Novo Nordisk INvestigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age equal to or above18 years at the time of signing informed consent
- Diagnosed with T2D at least 180 days prior to the day of screening
- HbA1c of 8-10% (64-86 mmol/mol) (both inclusive)
- Stable daily dose(s) for 90 days prior to the day of screening of:
- Any metformin formulations (equal to or above1500 mg or maximum tolerated or effective dose) alone or in combination with sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
- Renal impairment measured as estimated glomerular filtration rate (eGFR) value of <30 mL/min/1.73 m^2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation as defined by KDIGO 2012 classification
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Semaglutide 2.0 mg
All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached.
From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
|
Semaglutide injected subcutaneously (s.c., under the skin) once-weekly.
Participants will keep taking their pre-study diabetes tablets throughout the study.
|
ACTIVE_COMPARATOR: Semaglutide 1.0 mg
All participants will receive one injection per week during a 12-week dose escalation period.
From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.
|
Semaglutide injected subcutaneously (s.c., under the skin) once-weekly.
Participants will keep taking their pre-study diabetes tablets throughout the study.
Semaglutide placebo injected once-weekly from week 13 to week 40.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in glycosylated haemoglobin (HbA1c) was evaluated. Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first; and 'In-trial' observation period which started at the date of randomisation and ended at the first of the following dates, both inclusive: end-of-treatment visit (week 40), death, participant withdrew informed consent, last contact for participant lost to follow-up. |
Week 0, week 40
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Weight
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in body weight was evaluated.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first; and 'In-trial' observation period which started at the date of randomisation and ended at the first of the following dates, both inclusive: end-of-treatment visit (week 40), death, participant withdrew informed consent, last contact for participant lost to follow-up.
|
Week 0, week 40
|
Change in Fasting Plasma Glucose (FPG)
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in FPG was evaluated.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
|
Week 0, week 40
|
Change in Body Mass Index (BMI)
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in BMI was evaluated.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
|
Week 0, week 40
|
Change in Waist Circumference
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in waist circumference was evaluated.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
|
Week 0, week 40
|
Participants Who Achieved HbA1c < 7.0%
Time Frame: Week 40
|
Percentage of participants who achieved HbA1c < 7.0% is presented.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
Missing HbA1c assessment at week 40 was imputed using observed data from participants within same treatment group.
|
Week 40
|
Participants Who Achieved HbA1c ≤ 6.5%
Time Frame: Week 40
|
Percentage of participants who achieved HbA1c ≤ 6.5% is presented.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
Missing HbA1c assessment at week 40 was imputed using observed data from participants within same treatment group.
|
Week 40
|
Participants Who Achieved Weight Loss ≥5%
Time Frame: Week 40
|
Percentage of participants who achieved weight loss ≥5% is presented.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
Missing body weight assessment at week 40 was imputed using observed data from participants within same treatment group.
|
Week 40
|
Participants Who Achieved Weight Loss ≥10%
Time Frame: Week 40
|
Percentage of participants who achieved weight loss ≥10% is presented.
Results are based on the 'on-treatment without rescue medication' observation period, which started at the date of first dose of trial product to either first initiation of rescue medication or the day of last dose of trial product, whichever came first.
Missing body weight assessment at week 40 was imputed using observed data from participants within same treatment group.
|
Week 40
|
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Time Frame: Week 0 to week 47
|
Hypoglycaemic episodes defined as treatment-emergent if the onset of the episode occurs within the on-treatment observation period.
Severe or BG-confirmed symptomatic hypoglycaemia is an episode that required assistance from another person for recovery and blood glucose-confirmed by a plasma glucose value <3.1 mmol/L (56 milligrams per deciliter (mg/dL)) with symptoms consistent with hypoglycaemia.
Results are based on the 'on-treatment' observation period, which started at the date of first dose of trial product and ended at the first date of any of the following: the follow-up visit (week 47), the treatment discontinuation follow-up visit (end of treatment + 7 weeks), the date of last dose of trial product +49 days or the end-date for the 'in-trial' observation period.
|
Week 0 to week 47
|
Change in Pulse Rate
Time Frame: Week 0, week 40
|
Change from baseline (week 0) to week 40 in pulse rate is presented.
Results are based on the 'on-treatment' observation period, which started at the date of first dose of trial product and ended at the endpoint-specific end-date.
|
Week 0, week 40
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9535-4506
- U1111-1224-5162 (OTHER: World Health Organization (WHO))
- 2018-004529-96 (REGISTRY: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Novo Nordisk A/SActive, not recruitingDiabetes Mellitus, Type 2 | Peripheral Arterial DiseaseSpain, Taiwan, China, India, United States, Canada, Thailand, Austria, Malaysia, Germany, Poland, Japan, Czechia, Greece, Belgium, Denmark, Hungary, Latvia, Norway, Sweden
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SRecruiting
-
Novo Nordisk A/SActive, not recruitingEarly Alzheimer´s DiseaseCanada, United States, Taiwan, Netherlands, United Kingdom, Spain, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, China, Poland, Denmark, Czechia, Ireland, Japan, South Africa, Romania, S... and more
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, France, Spain, Taiwan, United Kingdom, Germany, India, Brazil, Canada, Japan, Malaysia, Russian Federation, Australia, Norway, Mexico, Netherlands, Portugal, Hungary, Italy, Austria, Greece, South Africa, Turkey, Finland, Puerto Rico and more